Literature DB >> 18008224

Seroprevalence of measles antibody in the US population, 1999-2004.

Geraldine M McQuillan1, Deanna Kruszon-Moran, Terri B Hyde, Bagher Forghani, William Bellini, Gustavo H Dayan.   

Abstract

BACKGROUND: Endemic measles transmission was declared eliminated in the United States in 2000. To ensure that elimination can be maintained, high population immunity must be sustained and monitored. Testing for measles antibody was included in the National Health and Nutrition Examination Survey (NHANES), a nationally representative survey, conducted during 1999-2004.
METHODS: A measles-specific immunoassay was used to measure the seroprevalence of measles antibody in NHANES participants 6-49 years of age. For analysis, participants were grouped by birth cohort.
RESULTS: During 1999-2004, the rate of measles seropositivity in the population overall was 95.9% (95% confidence interval [CI], 95.1%-96.5%). The highest seroprevalence of measles antibody was in non-Hispanic blacks (98.6% [95% CI, 98.0%-99.1%]). Those born during 1967-1976 had significantly lower levels of measles antibody (92.4% [95% CI, 90.8%-93.9%]) than did the other birth cohorts. Independent predictors of measles seropositivity in the 1967-1976 birth cohort were non-Hispanic/black race/ethnicity, more than a high school education, having health insurance, and birth outside the United States.
CONCLUSIONS: Measles seropositivity was uniformly high in the US population during 1999-2004. Nearly all population subgroups had evidence of measles seropositivity levels greater than the estimated threshold necessary to sustain measles elimination. Non-Hispanic whites and Mexican Americans born during 1967-1976 had the lowest measles seropositivity levels and represent populations that might be at increased risk for measles disease if the virus were reintroduced into the United States.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18008224     DOI: 10.1086/522866

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  35 in total

1.  Associations between demographic variables and multiple measles-specific innate and cell-mediated immune responses after measles vaccination.

Authors:  Benjamin J Umlauf; Iana H Haralambieva; Inna G Ovsyannikova; Richard B Kennedy; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Viral Immunol       Date:  2012-01-12       Impact factor: 2.257

2.  Race and sex-based differences in cytokine immune responses to smallpox vaccine in healthy individuals.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Richard B Kennedy; Beth R Larrabee; V Shane Pankratz; Gregory A Poland
Journal:  Hum Immunol       Date:  2013-06-24       Impact factor: 2.850

3.  Regional administration of oncolytic Echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer.

Authors:  Erin S Haley; Gough G Au; Brian R Carlton; Richard D Barry; Darren R Shafren
Journal:  J Mol Med (Berl)       Date:  2009-01-13       Impact factor: 4.599

4.  Seroepidemiology of measles in Beijing, China: a cross-sectional study.

Authors:  Zhujiazi Zhang; Meng Chen; Yiting Wang; Juan Li; Xiaomei Li; Li Lu
Journal:  Hum Vaccin Immunother       Date:  2019-05-22       Impact factor: 3.452

5.  Immunity to Measles, Mumps, and Rubella in US Children With Perinatal HIV Infection or Perinatal HIV Exposure Without Infection.

Authors:  George K Siberry; Kunjal Patel; William J Bellini; Brad Karalius; Murli U Purswani; Sandra K Burchett; William A Meyer; Sun Bae Sowers; Angela Ellis; Russell B Van Dyke
Journal:  Clin Infect Dis       Date:  2015-06-09       Impact factor: 9.079

6.  Missed Opportunities for Measles, Mumps, Rubella Vaccination Among Departing U.S. Adult Travelers Receiving Pretravel Health Consultations.

Authors:  Emily P Hyle; Sowmya R Rao; Emily S Jentes; Amy Parker Fiebelkorn; Stefan H F Hagmann; Allison Taylor Walker; Rochelle P Walensky; Edward T Ryan; Regina C LaRocque
Journal:  Ann Intern Med       Date:  2017-05-16       Impact factor: 25.391

7.  Measles in Healthcare Facilities in the United States During the Postelimination Era, 2001-2014.

Authors:  Amy Parker Fiebelkorn; Susan B Redd; David T Kuhar
Journal:  Clin Infect Dis       Date:  2015-05-15       Impact factor: 9.079

8.  Identifying postelimination trends for the introduction and transmissibility of measles in the United States.

Authors:  Seth Blumberg; Wayne T A Enanoria; James O Lloyd-Smith; Thomas M Lietman; Travis C Porco
Journal:  Am J Epidemiol       Date:  2014-04-30       Impact factor: 4.897

9.  Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses.

Authors:  Maria Cristina Ballesteros-Briones; Eva Martisova; Erkuden Casales; Noelia Silva-Pilipich; Maria Buñuales; Javier Galindo; Uxua Mancheño; Marta Gorraiz; Juan J Lasarte; Grazyna Kochan; David Escors; Alfonso R Sanchez-Paulete; Ignacio Melero; Jesus Prieto; Ruben Hernandez-Alcoceba; Sandra Hervas-Stubbs; Cristian Smerdou
Journal:  Mol Ther       Date:  2019-09-16       Impact factor: 11.454

Review 10.  Oncolytic measles virus strains as novel anticancer agents.

Authors:  Pavlos Msaouel; Mateusz Opyrchal; Evidio Domingo Musibay; Evanthia Galanis
Journal:  Expert Opin Biol Ther       Date:  2013-01-06       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.